Inhibikase Therapeutics Reports FY 2025 Financial Results
- Financial Performance: Inhibikase Therapeutics reported a GAAP EPS of -$0.49 for FY 2025, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position Improvement: As of December 31, 2025, the company held $178.8 million in cash, cash equivalents, and marketable securities, a significant increase from $97.5 million in 2024, enhancing financial flexibility for future investments.
- Increased R&D Expenses: Research and development expenses for 2025 totaled $29.8 million, including a $7.4 million non-cash write-off and $2.5 million in stock-based compensation related to the CorHepta acquisition, reflecting a strategic investment despite a rise from $17.2 million in 2024.
- Rising SG&A Costs: Selling, general, and administrative expenses reached $23.6 million in 2025, which included $1.0 million in severance costs due to senior executive transitions, significantly up from $11.4 million in 2024, indicating cost pressures amid management changes.
Trade with 70% Backtested Accuracy
Analyst Views on IKT
About IKT
About the author
Inhibikase Therapeutics Reports FY 2025 Financial Results
- Financial Performance: Inhibikase Therapeutics reported a GAAP EPS of -$0.49 for FY 2025, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position Improvement: As of December 31, 2025, the company held $178.8 million in cash, cash equivalents, and marketable securities, a significant increase from $97.5 million in 2024, enhancing financial flexibility for future investments.
- Increased R&D Expenses: Research and development expenses for 2025 totaled $29.8 million, including a $7.4 million non-cash write-off and $2.5 million in stock-based compensation related to the CorHepta acquisition, reflecting a strategic investment despite a rise from $17.2 million in 2024.
- Rising SG&A Costs: Selling, general, and administrative expenses reached $23.6 million in 2025, which included $1.0 million in severance costs due to senior executive transitions, significantly up from $11.4 million in 2024, indicating cost pressures amid management changes.
INHIBIKASE THERAPEUTICS INC: BOFA GLOBAL RESEARCH STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $6
Company Overview: Inhibikase Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative diseases.
Recent Developments: The company has received a "Buy" rating from analysts, indicating positive expectations for its future performance.
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Inhibikase Therapeutics Enhances Leadership with Timothy Pigot's Appointment as Chief Commercial and Strategy Officer
New Appointment: Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer, bringing extensive experience in the pharmaceutical industry, particularly in pulmonary arterial hypertension (PAH).
Leadership Insight: CEO Mark Iwicki expressed confidence in Pigot's expertise and connections within the PAH market, which will be crucial as the company advances its lead product candidate, IKT-001, towards late-stage clinical trials.
Company Background: Inhibikase Therapeutics focuses on developing therapies for cardiopulmonary diseases, specifically targeting PAH, a serious condition affecting around 50,000 Americans.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future activities and potential risks that could impact their progress and results.
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Company Developments: Inhibikase Therapeutics is advancing its lead product candidate, IKT-001, towards a Phase 2b clinical trial for Pulmonary Arterial Hypertension (PAH), with study initiation expected in the second half of 2025. The trial will evaluate different dosages of IKT-001 compared to placebo in approximately 150 participants.
Financial Overview: For the quarter ending June 30, 2025, Inhibikase reported a net loss of $9.9 million and cash reserves of $87.7 million, reflecting an increase in research and development expenses due to the acquisition of CorHepta and ongoing clinical trials.
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Company Developments: Inhibikase Therapeutics reported a net loss of $13.7 million for Q1 2025 and is preparing to initiate a Phase 2b clinical study of IKT-001 for pulmonary arterial hypertension (PAH) in the second half of 2025, with a strengthened leadership team in place.
Financial Overview: The company's research and development expenses surged to $10.5 million due to an acquisition, while cash reserves stood at $93.2 million as of March 31, 2025, reflecting ongoing investments in their PAH treatment initiatives.
Inhibikase Therapeutics Reports FY 2025 Financial Results
- Financial Performance: Inhibikase Therapeutics reported a GAAP EPS of -$0.49 for FY 2025, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position Improvement: As of December 31, 2025, the company held $178.8 million in cash, cash equivalents, and marketable securities, a significant increase from $97.5 million in 2024, enhancing financial flexibility for future investments.
- Increased R&D Expenses: Research and development expenses for 2025 totaled $29.8 million, including a $7.4 million non-cash write-off and $2.5 million in stock-based compensation related to the CorHepta acquisition, reflecting a strategic investment despite a rise from $17.2 million in 2024.
- Rising SG&A Costs: Selling, general, and administrative expenses reached $23.6 million in 2025, which included $1.0 million in severance costs due to senior executive transitions, significantly up from $11.4 million in 2024, indicating cost pressures amid management changes.
INHIBIKASE THERAPEUTICS INC: BOFA GLOBAL RESEARCH STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $6
Company Overview: Inhibikase Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative diseases.
Recent Developments: The company has received a "Buy" rating from analysts, indicating positive expectations for its future performance.
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Inhibikase Therapeutics Enhances Leadership with Timothy Pigot's Appointment as Chief Commercial and Strategy Officer
New Appointment: Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer, bringing extensive experience in the pharmaceutical industry, particularly in pulmonary arterial hypertension (PAH).
Leadership Insight: CEO Mark Iwicki expressed confidence in Pigot's expertise and connections within the PAH market, which will be crucial as the company advances its lead product candidate, IKT-001, towards late-stage clinical trials.
Company Background: Inhibikase Therapeutics focuses on developing therapies for cardiopulmonary diseases, specifically targeting PAH, a serious condition affecting around 50,000 Americans.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future activities and potential risks that could impact their progress and results.
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Company Developments: Inhibikase Therapeutics is advancing its lead product candidate, IKT-001, towards a Phase 2b clinical trial for Pulmonary Arterial Hypertension (PAH), with study initiation expected in the second half of 2025. The trial will evaluate different dosages of IKT-001 compared to placebo in approximately 150 participants.
Financial Overview: For the quarter ending June 30, 2025, Inhibikase reported a net loss of $9.9 million and cash reserves of $87.7 million, reflecting an increase in research and development expenses due to the acquisition of CorHepta and ongoing clinical trials.
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Company Developments: Inhibikase Therapeutics reported a net loss of $13.7 million for Q1 2025 and is preparing to initiate a Phase 2b clinical study of IKT-001 for pulmonary arterial hypertension (PAH) in the second half of 2025, with a strengthened leadership team in place.
Financial Overview: The company's research and development expenses surged to $10.5 million due to an acquisition, while cash reserves stood at $93.2 million as of March 31, 2025, reflecting ongoing investments in their PAH treatment initiatives.
